Immunology · Good Syndrome

Understanding Good Syndrome: Thymoma and Your Immune System

At a Glance

Good syndrome is a rare adult-onset immune deficiency linked to a thymoma. Removing the tumor does not usually restore immune function, so ongoing care often includes antibody replacement and monitoring for serious bacterial, viral, and fungal infections.

Good syndrome, also known as thymoma-hypogammaglobulinemia syndrome, is a rare, adult-onset condition where a thymoma (a tumor of the thymus gland) occurs alongside a serious immune system deficiency ^[1]^[2].

In a healthy body, the thymus helps train T cells to recognize friends from foes, while B cells develop in the bone marrow. In Good syndrome, an incompletely understood breakdown occurs, leaving the body unable to produce enough antibodies or mount an effective cellular response to fight off bacteria, viruses, and fungi ^[3]^[4]. Because it is estimated to affect only 2% to 5% of people with a thymoma, many general practitioners may never have encountered a case ^[5]^[6].

The Core Mechanism of the Syndrome

The “hypogammaglobulinemia” in the name refers to having low levels of antibodies (immunoglobulins) in the blood ^[1]. This occurs because of a profound drop in certain immune cells:

Absent B Cells: Most patients have markedly reduced or virtually absent circulating B cells, the specialized white blood cells responsible for making antibodies ^[7]^[8]. Research suggests these cells stop developing correctly in the bone marrow, though the exact link to the thymoma remains unclear ^[9].
T Cell Defects: The syndrome also affects T cells, which coordinate the immune response. Patients often have low “helper” T cell counts (CD4 cells) and an inverted ratio of different T cell types, making it harder for the body to clear unusual or “opportunistic” infections ^[1]^[7].

Why Surgery is Not a Cure

A common and understandable misunderstanding is that removing the thymoma will “fix” the immune system. Unfortunately, evidence shows that thymectomy (surgical removal of the thymus) does not reverse the immunodeficiency ^[10]^[11].

The immune defect often persists long-term or lifelong, or may even first appear years after the tumor has been successfully removed ^[12]^[13]. This is because the underlying problem involves a deep-seated dysregulation of how your body creates and trains immune cells, which continues even after the tumor is gone ^[9]^[14]. While surgery is standard for treating the tumor itself, your immune system will require separate, ongoing management.

Living with a Combined Immunodeficiency

Because Good syndrome affects both your “antibody” defense (humoral immunity) and your “cell-to-cell” defense (cellular immunity), you are at higher risk for a wide range of infections ^[1]^[15].

Bacterial Infections: These often affect the sinuses and lungs, potentially leading to chronic issues like bronchiectasis (permanent scarring and widening of the airways) ^[1]^[16].
Opportunistic Infections: You may be more susceptible to viruses like CMV (cytomegalovirus) or fungal infections like chronic thrush ^[1]^[17].

The standard approach to managing this risk is immunoglobulin replacement therapy (IVIG or SCIG). This involves regular infusions of antibodies collected from healthy donors to replace the ones your body cannot make ^[17]^[18]. These infusions do not cure the syndrome, nor do they replace the function of T cells or protect against all fungal and viral opportunistic infections, but they are a critical tool for preventing severe bacterial infections and hospitalizations ^[19]^[17]. Your care team will monitor your levels to ensure the treatment is tailored to you ^[17].

Common questions in this guide

What is Good syndrome?

Good syndrome is a rare condition in adults in which a thymoma occurs with low antibody levels and problems affecting B cells and T cells. This combined immune deficiency makes it harder to fight bacterial, viral, and fungal infections.

Will removing my thymoma cure Good syndrome?

No. Thymectomy treats the thymoma, but it usually does not restore immune function. The deficiency may persist long-term or lifelong, and it can sometimes become apparent after the tumor has been removed.

Why does Good syndrome increase the risk of infections?

Good syndrome affects both antibody defenses and T-cell defenses. Reduced or absent B cells limit antibody production, while low helper T-cell counts and altered T-cell ratios can make unusual infections harder to control. This can lead to recurrent sinus or lung infections and opportunistic viral or fungal infections.

How is the immune deficiency in Good syndrome treated?

Regular immunoglobulin replacement, given through a vein as IVIG or under the skin as SCIG, supplies antibodies collected from healthy donors. It can reduce severe bacterial infections and hospitalizations, but it does not cure Good syndrome, replace T-cell function, or protect against every viral or fungal infection.

What should be monitored in someone with Good syndrome?

A care team may monitor IgG, IgA, and IgM levels, peripheral B-cell counts, and T-cell counts and ratios. These results help tailor immunoglobulin replacement and may help the team decide whether preventive treatment for certain opportunistic infections is needed.

Can I receive vaccines if I have Good syndrome?

Vaccine decisions should be individualized with an immunologist because Good syndrome affects both antibody and T-cell defenses. Ask your care team which vaccines are recommended and which should be avoided, and do not change your vaccine plan without their advice.

Curated prompts to bring to your next appointment.

1.What are my current levels of IgG, IgA, and IgM, and how do they compare to the targets for someone with Good syndrome?
2.How low are my peripheral B cell counts, and what does this mean for my ability to produce new antibodies?
3.Based on my T cell counts and ratios, should I be on preventative medications for opportunistic infections like CMV or PJP?
4.What is the schedule for my immunoglobulin replacement therapy, and what 'trough' level are we aiming for?
5.Since my thymoma is being (or has been) removed, who will be the lead specialist managing my long-term immune health?
6.What specific vaccines are still recommended for me, and which ones must I avoid?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

Good syndrome combines thymoma with low antibody levels and defects in B cells and T cells, creating a combined immune deficiency.
Thymectomy treats the thymoma but does not usually reverse the immune deficiency, which may persist long-term or lifelong or appear after tumor removal.
People with Good syndrome are at increased risk for recurrent bacterial sinus and lung infections, CMV, chronic thrush, and other opportunistic infections; bronchiectasis can develop after repeated lung infections.
IVIG or SCIG replaces missing antibodies and helps prevent severe bacterial infections and hospitalizations, but it does not cure the syndrome or replace T-cell function.
Long-term care may include monitoring immunoglobulin levels and B- and T-cell counts, with coordination among immunology, oncology, and surgical teams.

References (19)

1
Prevention of infectious diseases in patients with Good syndrome.
Multani A, Gomez CA, Montoya JG
Current opinion in infectious diseases 2018; (31(4)):267-277 doi:10.1097/QCO.0000000000000473.
PMID: 29878906
2
Good's syndrome: brief overview of an enigmatic immune deficiency.
Sipos F, Műzes G
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2023; (131(12)):698-704 doi:10.1111/apm.13351.
PMID: 37729389
3
Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.
Lippner EA, Lewis DB, Robinson WH, Katsumoto TR
Current treatment options in oncology 2019; (20(7)):62 doi:10.1007/s11864-019-0661-2.
PMID: 31227926
4
Atypical presentation of Good syndrome: acute hepatitis from hepatitis B virus reactivation.
Lai YW, Tan TC
Asia Pacific allergy 2020; (10(4)):e37 doi:10.5415/apallergy.2020.10.e37.
PMID: 33178562
5
Immunological spectrum in patients with thymoma: beyond good syndrome.
Sönmez E, Kalkan F, Balaban Y, et al.
Immunologic research 2026; (74(1)).
PMID: 42390792
6
Delayed Diagnosis and Complications of Predominantly Antibody Deficiencies in a Cohort of Australian Adults.
Slade CA, Bosco JJ, Binh Giang T, et al.
Frontiers in immunology 2018; (9()):694 doi:10.3389/fimmu.2018.00694.
PMID: 29867917
7
In-depth blood immune profiling of Good syndrome patients.
Torres-Valle A, Aragon L, Silva SL, et al.
Frontiers in immunology 2023; (14()):1285088 doi:10.3389/fimmu.2023.1285088.
PMID: 38035080
8
Good's Syndrome Mirrors a Combined Immunodeficiency with Anti-Cytokine Antibodies in the Total Absence of B Cells.
Kabir A, Gilbert L, Almasizadeh D, et al.
Journal of clinical immunology 2026; (46(1)).
PMID: 41701387
9
Precursor B-cell development in bone marrow of Good syndrome patients.
Del Pino Molina L, Wentink M, van Deuren M, et al.
Clinical immunology (Orlando, Fla.) 2019; (200()):39-42 doi:10.1016/j.clim.2018.11.009.
PMID: 30690192
10
Pure Red Cell Aplasia and Other Haematological Diseases Associated With Thymoma: A Case Series and Systematic Review.
Yen CC, Huang WL, Li SS, et al.
Frontiers in medicine 2021; (8()):759914 doi:10.3389/fmed.2021.759914.
PMID: 34966753
11
Thymic epithelial tumor complicated by immunological abnormalities: results from a single-center retrospective study in China.
Shi TY, Wen XH, Shi XH, Lu YW
Journal of thoracic disease 2019; (11(4)):1580-1588 doi:10.21037/jtd.2019.02.90.
PMID: 31179102
12
Immunodeficiency and Thymoma: A Case Report on Good Syndrome, a Diagnosis Frequently Missed and Forgotten.
Tang ASO, Loh WH, Wong QY, et al.
The American journal of case reports 2021; (22()):e928659 doi:10.12659/AJCR.928659.
PMID: 33712551
13
Clinical Characteristics, Surgical Risks, and Long-Term Prognosis of Good's Syndrome.
Otsuka S, Shiiya H, Sasaki A, et al.
Cureus 2026; (18(6)):e111036 doi:10.7759/cureus.111036.
PMID: 42491992
14
Acquired T-Cell Immunodeficiency in Thymoma Patients.
Christopoulos P, Fisch P
Critical reviews in immunology 2016; (36(4)):315-327 doi:10.1615/CritRevImmunol.2017018916.
PMID: 28322136
15
Characteristics of Good's Syndrome in China: A Systematic Review.
Dong JP, Gao W, Teng GG, et al.
Chinese medical journal 2017; (130(13)):1604-1609 doi:10.4103/0366-6999.208234.
PMID: 28639577
16
Good syndrome combined with multiple microbial pulmonary infections: case report and review of the literature.
Ye Y, Wang J, Bao B, et al.
Immunologic research 2024; (72(6)):1288-1298 doi:10.1007/s12026-024-09528-y.
PMID: 39180607
17
Features and outcomes of immunoglobulin therapy in patients with Good syndrome at Thailand's largest tertiary referral hospital.
Thongngarm T, Boonyasiri A, Pradubpongsa P, et al.
Asian Pacific journal of allergy and immunology 2019; (37(2)):109-115 doi:10.12932/AP-131117-0196.
PMID: 29888926
18
Good's syndrome presenting with CMV pneumonitis and oesophageal candidiasis: A case report.
Kwok CT, Yeung YC
Respirology case reports 2022; (10(1)):e0888 doi:10.1002/rcr2.888.
PMID: 34888060
19
Clinical and laboratory features of seventy-eight UK patients with Good's syndrome (thymoma and hypogammaglobulinaemia).
Zaman M, Huissoon A, Buckland M, et al.
Clinical and experimental immunology 2019; (195(1)):132-138 doi:10.1111/cei.13216.
PMID: 30216434

This page is for informational purposes only and does not constitute medical advice. It cannot interpret your immune tests or replace individualized guidance from your immunologist, oncologist, or surgeon.

Get notified when new evidence is published on Thymoma-hypogammaglobulinemia syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents